At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,170 enrolled
Drug / intervention
risankizumabbiological
Likely dose
risankizumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
In Brief
A Phase 3 clinical trial evaluating risankizumab for Psoriasis. Completed, enrolled 2,170 participants across 233 sites in 17 countries.
Detailed Summary
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartFeb 2017
Primary CompletionNov 2023
TodayJul 2026
First PostedFeb 9, 2017
Enrollment StartFeb 27, 2017
Primary CompletionNov 29, 2023
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 9.4 years ago
Interventions
risankizumabbiological
Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.